55502-94-8

Basic information

• Product Name: 2-AMino-5-ethyl-thiophene-3-carboxylic acid
• Synonyms: 2-AMino-5-ethyl-thiophene-3-carboxylic acid
• CAS NO: 55502-94-8
• Molecular Formula: C7H9NO2S
• Molecular Weight: 171
• Mol File: 55502-94-8.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-AMino-5-ethyl-thiophene-3-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-AMino-5-ethyl-thiophene-3-carboxylic acid(55502-94-8)
• EPA Substance Registry System: 2-AMino-5-ethyl-thiophene-3-carboxylic acid(55502-94-8)

Safety Data

• Hazardous Substances Data: 55502-94-8(Hazardous Substances Data)

Usage

General Description

2-Amino-5-ethyl-thiophene-3-carboxylic acid is a chemical compound with a molecular formula C8H11NO3S. It is an organic compound that contains a thiophene ring with an amino group and a carboxylic acid group attached at the 3rd and 5th positions, respectively. 2-AMino-5-ethyl-thiophene-3-carboxylic acid is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. It has properties that make it useful in the development of new drugs and materials. Additionally, 2-Amino-5-ethyl-thiophene-3-carboxylic acid is also used in research and development processes in the pharmaceutical and chemical industries.

Upstream product

• 4507-13-5 ethyl 2-amino-5-ethylthiophene-3-carboxylate 

Downstream Products

• 1084628-04-5 C₁₇H₁₄N₄O₂S 

Relevant articles and documents

A class of 5-nitro-2-furancarboxylamides with potent trypanocidal activity against Trypanosoma brucei in vitro

Recently, the World Health Organization approved the nifurtimox- eflornithine combination therapy for the treatment of human African trypanosomiasis, renewing interest in nitroheterocycle therapies for this and associated diseases. In this study, we have synthesized a series of novel 5-nitro-2-furancarboxylamides that show potent trypanocidal activity, ～1000-fold more potent than nifurtimox against in vitro Trypanosoma brucei with very low cytotoxicity against human HeLa cells. More importantly, the most potent analogue showed very limited cross-resistance to nifurtimox-resistant cells and vice versa. This implies that our novel, relatively easy to synthesize and therefore cheap, 5-nitro-2-furancarboxylamides are targeting a different, but still essential, biochemical process to those targeted by nifurtimox or its metabolites in the parasites. The significant increase in potency (smaller dose probably required) has the potential for greatly reducing unwanted side effects and also reducing the likelihood of drug resistance. Collectively, these findings have important implications for the future therapeutic treatment of African sleeping sickness.